Approval · Notice of Compliance 8167 · 2006
MACUGEN: Notice of Compliance 8167
Issued July 24, 2006
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 8167
- Date
- July 24, 2006
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revised product monograph - 2 year efficacy and safety results from studies in age-related macular degeneration
- Therapeutic class
- Anti-vascular endothelium growth factor (vegf 165 inhibitor) for age-related macular degeneration
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MACUGEN | Not yet assigned | — |
Medicinal ingredients
- PEGAPTANIB 0.3 MG per 90MCL